Lv4
410 积分 2021-03-22 加入
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
12天前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
12天前
已完结
Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review
28天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
1个月前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
1个月前
已完结
Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
1个月前
已完结
Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
1个月前
已完结
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
1个月前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
1个月前
已完结
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer
1个月前
已完结
皖公网安备34019202002308
